FDA approves perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible MIBC.
1/5 보강
OpenAlex 토픽 ·
Cancer Immunotherapy and Biomarkers
Advanced Breast Cancer Therapies
Cancer, Stress, Anesthesia, and Immune Response
APA
Leah Lawrence (2026). FDA approves perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible MIBC.. Cancer, 132(8), e70355. https://doi.org/10.1002/cncr.70355
MLA
Leah Lawrence. "FDA approves perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible MIBC.." Cancer, vol. 132, no. 8, 2026, pp. e70355.
PMID
42011744 ↗
같은 제1저자의 인용 많은 논문 (5)
- Tarlatamab plus anti-PD-L1 as first-line maintenance for ES-SCLC demonstrates promising results.
- Adding pembrolizumab to a platinum doublet may be a new option for advanced penile cancer.
- Two new options for NPM1-mutated relapsed, refractory acute myeloid leukemia: Researchers are looking into whether revumenib or ziftomenib can be combined with first-line standard-of-care treatment options.
- Joint guideline update recommendations for postmastectomy radiation therapy: The guideline task force identified several key radiation therapy questions for patients with breast cancer who undergo mastectomy.
- Oral TKI sevabertinib approved for advanced HER2-mutant NSCLC.